ID1201, the ethanolic extract of the fruit of Melia toosendan ameliorates impairments in spatial learning and reduces levels of amyloid beta in 5XFAD mice
Abstract
A previous study has demonstrated the anti-amyloidogenic effects of the ethanolic extract of Meliae Fructus (ID1201) using cell lines with stably expressed human Swedish mutant APP695 and β-secretase 1, and 5Xfamilial AD (FAD) mice carrying five mutations. Here, we investigated the effects of ID1201 on cognitive impairment in 5XFAD mice. Daily administration of ID1201 was commenced at 3 months of age and continued for 3 months. Mice were serially trained in cued/response and place/spatial training tasks in the Morris water maze. After this training, testing for strategy preference was conducted. Non-transgenic control mice with vehicle treatment, vehicle-treated 5XFAD, and ID1201-treated 5XFAD mice showed equivalent performance in cued/response training. However, as training progressed to the subsequent place/spatial learning, vehicle-treated control and ID1201-treated 5XFAD mice differed significantly from vehicle-treated 5XFAD mice in measures of spatial learning (search error and adaptive spatial learning strategy). In the strategy preference test that followed, control mice preferred a place/spatial strategy relative to vehicle-treated 5XFAD mice, but differences between ID1201-treated 5XFAD mice and vehicle-treated 5XFAD mice were not significant. Additionally, ID1201 treatment reduced hippocampal levels of insoluble Aβ42 and increased cortical levels of soluble amyloid precursor protein α. These results indicate that ID1201 may possess potential as a therapeutic agent for Alzheimer's disease by decreasing Aβ deposits.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical trials for APH-1105 and ID1201, two α-secretase modulators that stimulate the PI3K/Akt pathway, are now underway.
“Clinical trials for APH-1105 and ID1201, two -secretase modulators that stimulate the PI3K/Akt pathway, are now underway.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Cho et al., 2014
APH-1105 is an intranasal therapy for mild to moderate Alzheimer's disease, while ID1201 also activates α-secretase and is studied in subjects with mild Alzheimer's disease.
“APH-1105 is an intranasal therapy for mild to moderate AD while ID1201 also activates α -secretase and is studied in subjects with mild AD (Cho et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Cho et al., 2014
ID1201 is a fruit extract of melia toosendan and induces α-secretase activation; it is evaluated in mild Alzheimer disease.
“ID1201 is a fruit extract of melia toosendan and also induces α-secretase activation. It is evaluated in mild AD.47”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [47]
Restricted knowledge assumes that α-secretase activation is promoted through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and may be through γ-aminobutyric acid (GABA) receptor signaling; thus, agents that activate the PI3K/Akt pathway or act as selective GABA receptor modulators are suggested as potential therapeutic drugs for Alzheimer disease.
“Restricted, nowadays, knowledge assumes that α-secretase activation is promoted through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and may be through γ-aminobutyric acid (GABA) receptor signaling; thus, agents that activate the PI3K/Akt pathway or act as selective GABA receptor modulators are suggested as potential therapeutic drugs for AD.47,48”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [47]
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482 · see citing works
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · see citing works
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,588 · see citing works
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438 · see citing works
Gallagher, M., Burwell, R. D., & Burchinal, M. A. (2015) · Behavioral Neuroscience · doi:10.1037/bne0000080 · Cited by 861 · see citing works
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 816 · see citing works
McDonald, R. J., & White, N. M. (1994) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(05)80009-3 · Cited by 722 · see citing works
Gallagher, M., Burwell, R. D., & Burchinal, M. (1993) · Behavioral Neuroscience · doi:10.1037/0735-7044.107.4.618 · Cited by 675 · see citing works
Kimura, R., & Ohno, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.006 · Cited by 333 · see citing works
Cognitive and neurobiologic markers of early Alzheimer disease
Albert, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13547 · Cited by 243 · see citing works
Search Strategies Used byAPPTransgenic Mice During Navigation in the Morris Water MazePreprint
Janus, C. (2004) · Learning & Memory · doi:10.1101/lm.70104 · Cited by 194 · see citing works
Solano, D. C., Sironi, M., Bonfini, C., Solerte, S. B., Govoni, S. M., & Racchi, M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.1015 · Cited by 175 · see citing works
Girard, S. D., Jacquet, M., Baranger, K., Migliorati, M., Escoffier, G., Bernard, A., Khrestchatisky, M., Féron, F., Rivera, S., Roman, F. S., et al. (2014) · Hippocampus · doi:10.1002/hipo.22267 · Cited by 119 · see citing works
Girard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., Marchetti, E., Khrestchatisky, M., Rivera, S., & Roman, F. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120982 · Cited by 107 · see citing works
Urano, T., & Tohda, C. (2010) · Phytotherapy Research · doi:10.1002/ptr.3183 · Cited by 101 · see citing works
Lichtenthaler, S. F., & Haass, C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21746 · Cited by 88 · see citing works
Mei, Z., Zhang, F., Tao, L., Zheng, W., Cao, Y., Wang, Z., Tang, S., Le, K., Chen, S., Pi, R., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.013 · Cited by 82 · see citing works
Shi, C., Zheng, D., Li, F., Wu, F., Kwong, W. H., & Xu, J. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.12.005 · Cited by 81 · see citing works
Bandyopadhyay, S., & Rogers, J. T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.032 · Cited by 75 · see citing works
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., & Wirths, O. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.006 · Cited by 46 · see citing works
Emergence of a Cue Strategy Preference on the Water Maze Task in Aged C57B6 × SJL F1 Hybrid MicePreprint
Nicolle, M. M., Prescott, S., & Bizon, J. L. (2003) · Learning & Memory · doi:10.1101/lm.64803 · Cited by 45 · see citing works
Cryptotanshinione upregulates α-secretase by activation PI3K pathway in cortical neurons
Mei, Z., Situ, B., Tan, X., Zheng, S., Zhang, F., Yan, P., & Liu, P. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.083 · Cited by 39 · see citing works
Joyashiki, E., Matsuya, Y., & Tohda, C. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2010.541571 · Cited by 37 · see citing works
Shi, C., Wu, F., Xu, J., & Zou, J. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.03.028 · Cited by 28 · see citing works
Park, H., Yoo, J.-S., Kim, J., Hwang, B. Y., Han, J., Yeon, S.-W., & Kang, J. (2014) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.01.008 · Cited by 17 · see citing works
Effect of Ampelopsis radix on the Toxicity of Adriamycin
Kim, D., Lee, S.-H., & Jeong, Y.-B. (1994) · The Korean Journal of Food And Nutrition · Cited by 1 · see citing works
Flagged first, then by citations
2 of the 28 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330 · see citing works
“Ongoing clinical trials with active or passive immunotherapy agents [26], with agents that reduce the Aβ plaque burden [27,28], with α-secretase modulators [29] or BACE inhibitors [25] are enrolling prodromal or mild AD patients to test the hypothesis of early pharmacological intervention [3,8].”
BackgroundAn update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122 · see citing works
Medrano-Jiménez, E., Jiménez-Ferrer, I., Pedraza‐Escalona, M., Ramírez-Serrano, C. E., Álvarez‐Arellano, L., Cortés‐Mendoza, J., Herrera-Ruiz, M. L., Jiménez‐Ferrer, E., Zamilpa, A., Tortoriello, J., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1515-3 · Cited by 98 · see citing works
Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Wu, T., Ding, L., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., Mou, C., Ye, M., & Zheng, Y. (2022) · Aging and Disease · doi:10.14336/ad.2022.0412 · Cited by 75 · see citing works
“In one investigation conducted on 5Xfamilial AD (FAD) mice, ID1201 treatment reduced insoluble Aβ42 and increased sAPPα level, indicating that it could be used to treat AD [66].”
BackgroundTherapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 47 · see citing works
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 32 · see citing works
“Agents targeting these pathways can also have drug prospects for AD (Cho et al. 2014).”
BackgroundChang, H., Wang, C., Gong, L., Zhang, Y., Liang, C., & Liu, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113795 · Cited by 20 · see citing works
4-Hydroxynonenal Immunoreactivity Is Increased in the Frontal Cortex of 5XFAD Transgenic Mice
Shin, S.-W., Kim, D.-H., Jeon, W. K., & Han, J. (2020) · Biomedicines · doi:10.3390/biomedicines8090326 · Cited by 17 · see citing works
“Each mouse that participated in the behavioral task was sacrificed 7 days following the competition test [20,22].”
MethodS, G. S., Raghu, C. H., & Fayaz, S. M. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210920120612 · Cited by 13 · see citing works
Kurdakova, A. (2016) · doi:10.53846/goediss-5882
“Several groups used this model in preclinical studies investigating possible treatments and their effects on the progression of cognitive impairment (Aytan et al. 2013; Bhattacharya et al. 2014; Cho et al. 2014; Fiol-deRoque et al. 2013; Hillmann et al. 2012; Wirths et al. 2010a).”
MethodYoung, R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc242.pub2
- Authors
- Cho, W.-H., Park, J.-C., Kim, D.-H., Kim, M.-S., Lee, S.-Y., Park, H., Kang, J.-H., Yeon, S.-W., & Han, J.-S.
- Affiliations
- Konkuk University (KR)
- Ildong (South Korea) (KR)
- Corresponding author
- Han, Jung-Soo
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 583
- Pages
- 170-175
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2121646700
- Cited by
- 13
- References
- 28
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2016: 1 · 2015: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Research Foundation Grant (KRF-2010-0023880)
- ILDONG Pharmaceutical Co. Ltd
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Melia toosendan, ethanolic fruit extract, Alzheimer's disease, amyloid-beta, 5xFAD mice, spatial learning, hippocampus, amyloid deposition, cognitive impairment
- MeSH terms
- Ethanol, Animals, Cerebral Cortex, Female, Fruit, Male, Mice, Mutant Strains, Plant Extracts, Solvents, Amyloid beta-Peptides, Maze Learning, Melia, Spatial Learning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
